İçeriğe geç

Jorge Barriuso

@drjorgebarriuso.bsky.social did:plc:la5yqfbrpcahwwqd3f75k4og

Consultant (clinician-scientist) in medical oncology with an interest in Lower GI malignancies including appendix tumours and peritoneal metastasis. #H12O #imas12 #rarecancers #translationalresearch #drugdevelopment

Bluesky’a katılma tarihi:

Takipçi
51
Takip edilen
17
Post
28
Sıralamaya girdiği gün
0

Özet

Jorge Barriuso (@drjorgebarriuso.bsky.social), 25 Kasım 2024 tarihinde katılan bir Bluesky kullanıcısı. 51 takipçisi var, 17 hesabı takip ediyor ve 28 post paylaştı.

Sıralama geçmişi

Bu hesabın postlarının Debya günlük listesine girdiği en iyi günler.

Bu hesap henüz günlük sıralamaya girmedi.

Son beğendiği postlar

Bluesky ağındaki herkese açık beğeniler.

  • ESMO - European Society for Medical Oncology@myesmo.bsky.social

    #ESMO26: Changing the cytotoxic payload may help to overcome resistance to antibody–drug conjugates (#ADCs). Rachel Abelman discusses studies investigating this strategy to improve patient responses in #BreastCancer #InsightsbyESMO ➡️ https://ow.ly/96mf5100brC

    Postu göster
  • ESMO - European Society for Medical Oncology@myesmo.bsky.social

    #ESMO26: Early-phase #ClinicalTrial results with the novel bispecific antibodies, pumitamig and opamtistomig, reflect a growing body of research in #NeuroendocrineCarcinoma #InsightsbyESMO ➡️ https://ow.ly/oxLC5100p7J #NENs #NECs #RareCancers

    Postu göster
  • ESMO - European Society for Medical Oncology@myesmo.bsky.social

    👉 #ESMONovelTherapies27: Novel therapies are changing oncology. Are you ready to optimise them in practice? -Understand the science -Select the right patients -Navigate treatment sequencing -Manage toxicities 🔗 https://ow.ly/vIkz50ZZAHh

    Postu göster
  • ESMO - European Society for Medical Oncology@myesmo.bsky.social

    #ESMO26: Preliminary data support encorafenib and cetuximab #rechallenge in metastatic colorectal cancer (#mCRC), although questions remain around patient selection and treatment specifications, as discussed by Rona Yaeger 🔗 https://ow.ly/6bmH5100p2M #InsightsbyESMO

    Postu göster
  • ESMO - European Society for Medical Oncology@myesmo.bsky.social

    #ESMO26: Phase III PERSEE #ClinicalTrial reports a 44% reduction in the risk of progression or death with the addition of #chemotherapy to pembrolizumab versus pembrolizumab alone in first-line advanced #NSCLC with #PD-L1 ≥50% ➡️ https://ow.ly/eWmC5100p3O #InsightsbyESMO Alfredo Addeo

    Postu göster

Daha fazlası için üye girişi yap

Blokladığı hesaplar

Bluesky’da bloklar herkese açık kayıtlardır.

Bu hesap kimseyi bloklamıyor.